research report · AMGN

Amgen Inc

Johannes Vermeer, Woman Holding a Balance, c. 1664, detail · National Gallery of Art

Viridis’s deep research report, written Nov 4, 2026 from its quarterly report (10-Q for the quarter ended Sep 30, 2026, filed Nov 4, 2026). Written and checked with Anthropic’s Claude models.

your email, no card; what you get

business trajectory

Improving

better on balance: sales, margins, cash or competitive position

financial resilience

Strong

can meet its obligations and fund its plan for two years with money it can count on, with room

Judgments of the business from its filings, not of its shares: no valuation, no advice.

bottom line

Amgen is outgrowing the patent cliff on its former best-seller. Third-quarter 2026 revenue rose 8% to $10.4B on volume. Eight growing brands added about $1.48B of quarterly sales, against a $758M fall in Prolia and XGEVA (my calculation). Underlying operating income rose about 9%, well below the 47% GAAP figure. Cash flow funds the dividend and investment with room. The decisive risks are an IRS claim of about $8.7B in tax, plus penalties and interest, and Medicare price-setting that reaches Otezla in 2027 and may reach Repatha as early as 2029.

what changed this quarter

  • Results: revenue was $10,365M vs $9,557M a year earlier. GAAP diluted EPS was $7.08 vs $5.93, and non-GAAP EPS $6.45 vs $5.64.
  • Free cash flow: $3.7B vs $4.2B. Amgen cites working capital, with Q3 2025 helped by the timing of rebates and collections.
  • 2026 guidance: revenue $38.9B–$39.7B, non-GAAP EPS $22.90–$23.70, capital spending about $2.6B, and buybacks of up to $3.0B. Management says the revenue and EPS ranges were raised but does not restate the old ones.
  • TAVNEOS: the European Commission revoked its EU authorization in August 2026. The U.S. withdrawal proposal is pending, against a $2.2B intangible asset.
  • IRS: a September 2026 draft notice asserts penalties for 2016–2018. The Tax Court ruling is now expected no earlier than late 2026 or early 2027, later than the 10-K's "second half of 2026".

in the full report

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

  • New brands are outrunning the denosumab patent cliff
  • Underlying profit grew about 9–15%, not 47%
  • The IRS dispute is the largest exposure, and it is widening
  • Pricing pressure is broadening, and 2027 is the test

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

read it whole

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what AMGN files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on AMGN say?” Add Viridis to Claude, or to ChatGPT.